genprowebdirectory
Facebook Linkedin RSS Twitter Youtube
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • A-Lists
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Search
Facebook Linkedin RSS Twitter Youtube
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
Genetic Engineering & Biotechnology News GEN – Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News Genetic Engineering & Biotechnology News
  • GEN Edge
    • Featured News
    • Multimedia
  • News
    • Insights
  • Topics
    • Artificial Intelligence
    • Bioprocessing
    • Cancer
    • Drug Discovery
    • Genome Editing
    • Infectious Diseases
    • OMICs
    • Translational Medicine
  • Magazine
    • Browse Issues
    • Subscribe
  • Multimedia
    • Summits
    • Webinars
    • GEN Live
    • Learning Labs
    • Podcasts
  • Resources
    • A-Lists
    • eBooks/Perspectives
    • Tutorials
    • Peer-Reviewed Journals
      • GEN Biotechnology
      • Re:Gen Open
    • New Products
    • Conference Calendar
  • Subscribe
    • Get GEN Magazine
    • Get GEN eNewsletters
Home 2024

Antitrust laws

StockWatch: “Final Resolution” Set for Illumina’s Grail Saga
GEN Edge

StockWatch: “Final Resolution” Set for Illumina’s Grail Saga

Illumina Links Grail Divestiture to Losing European Or U.S. Appeals
Industry News

Illumina Links Grail Divestiture to Losing European Or U.S. Appeals

Pharmaceutical Antitrust Enforcement in the Trump Administration
Insights

Pharmaceutical Antitrust Enforcement in the Trump Administration

Nestlé Health Science Invests $145M in Aimmune under Food Allergy Collaboration
Industry News

Nestlé Health Science Invests $145M in Aimmune under Food Allergy Collaboration

Court’s “Hard” Stance Will Hinder Innovators
Insights

Court’s “Hard” Stance Will Hinder Innovators

Akorn Acquiring VersaPharm for $440M
News

Akorn Acquiring VersaPharm for $440M

Valeant Portfolio Shows More Skin with $360M Obagi Deal
Industry News

Valeant Portfolio Shows More Skin with $360M Obagi Deal

PerkinElmer Acquires CambridgeSoft and Completes Deal for ArtusLabs
News

PerkinElmer Acquires CambridgeSoft and Completes Deal for ArtusLabs

Ninth Circuit Rules on IP and Antitrust Issues
Insights

Ninth Circuit Rules on IP and Antitrust Issues

Patent Ambushing Sullies Standard Setting
Insights

Patent Ambushing Sullies Standard Setting

12Page 1 of 2

Read the Digital Edition

June 2024 cover

Explore

  • About GEN
  • Contact GEN
  • GEN Staff
  • Editorial Guidelines
  • Reprints and Permissions
  • Scientific Advisory Board

Advertise

  • Media Kit and Planning Calendar
  • Advertising Terms and Conditions

Resources

  • Get the GEN Magazine
  • Get the GEN Email Newsletter
  • Inside Precision Medicine
  • Privacy Policy
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up